Efficacy and Safety of Ertugliflozin in Patients with Overweight and Obesity with Type 2 Diabetes Mellitus.

CONCLUSIONS: Meaningful reductions in HbA1c, fasting plasma glucose, BW, and SBP were observed with ertugliflozin in patients with overweight and obesity with type 2 diabetes mellitus. Ertugliflozin improved HbA1c and SBP and reduced BW across BMI subgroups. Ertugliflozin was generally well tolerated. PMID: 32202075 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/32202075?dopt=Abstract

Source: Obesity - March 25, 2020 Category: Eating Disorders & Weight Management Authors: Heymsfield SB, Raji A, Gallo S, Liu J, Pong A, Hannachi H, Terra SG Tags: Obesity (Silver Spring) Source Type: research